| Bradford A Anderson, MD | |
|
2441 F St, Bakersfield, CA 93301-3821 | |
| (661) 324-4716 | |
| (661) 321-0499 |
| Full Name | Bradford A Anderson |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 39 Years |
| Location | 2441 F St, Bakersfield, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891806832 | NPI | - | NPPES |
| 770255255 | Other | AR | TAX ID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2081P2900X | Physical Medicine & Rehabilitation - Pain Medicine | G60265 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kern Medical Center | Bakersfield, CA | Hospital |
| Entity Name | Bradford Anderson M.d. Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609113869 PECOS PAC ID: 1557514718 Enrollment ID: O20130122000069 |
News Archive
The Wall Street Journal on Monday examined how some hospitals are "adopting a policy to improve their finances: making medical care contingent on upfront payments."
Patients treated with definitive concurrent chemotherapy and radiation therapy (CCRT) for stage III non-small cell lung cancer (NSCLC) have longer overall survival when treated by highly experienced facilities, whether or not they are academic or community cancer centers.
Huntsman Cancer Institute researchers Michael Deininger, M.D., Ph.D., and Thomas O'Hare, Ph.D., were part of a team that found a potent oral drug, ponatinib, effective in patients who have developed resistance to standard treatments for chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic lymphoma.
GlaxoSmithKline plc announced today that a peer-reviewed study issued online by the New England Journal of Medicine has reported that GSK's FluLaval® Quadrivalent reduced flu cases among children ages 3-8 by 55.4% overall and lowered the risk of developing moderate-to-serious flu illness by 73.1%.
› Verified 8 days ago
| Entity Name | Kern County Hospital Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376623538 PECOS PAC ID: 4688964521 Enrollment ID: O20160915002690 |
News Archive
The Wall Street Journal on Monday examined how some hospitals are "adopting a policy to improve their finances: making medical care contingent on upfront payments."
Patients treated with definitive concurrent chemotherapy and radiation therapy (CCRT) for stage III non-small cell lung cancer (NSCLC) have longer overall survival when treated by highly experienced facilities, whether or not they are academic or community cancer centers.
Huntsman Cancer Institute researchers Michael Deininger, M.D., Ph.D., and Thomas O'Hare, Ph.D., were part of a team that found a potent oral drug, ponatinib, effective in patients who have developed resistance to standard treatments for chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic lymphoma.
GlaxoSmithKline plc announced today that a peer-reviewed study issued online by the New England Journal of Medicine has reported that GSK's FluLaval® Quadrivalent reduced flu cases among children ages 3-8 by 55.4% overall and lowered the risk of developing moderate-to-serious flu illness by 73.1%.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bradford A Anderson, MD 8701 Camino Media Ste C, Bakersfield, CA 93311-1336 Ph: (661) 324-4737 | Bradford A Anderson, MD 2441 F St, Bakersfield, CA 93301-3821 Ph: (661) 324-4716 |
News Archive
The Wall Street Journal on Monday examined how some hospitals are "adopting a policy to improve their finances: making medical care contingent on upfront payments."
Patients treated with definitive concurrent chemotherapy and radiation therapy (CCRT) for stage III non-small cell lung cancer (NSCLC) have longer overall survival when treated by highly experienced facilities, whether or not they are academic or community cancer centers.
Huntsman Cancer Institute researchers Michael Deininger, M.D., Ph.D., and Thomas O'Hare, Ph.D., were part of a team that found a potent oral drug, ponatinib, effective in patients who have developed resistance to standard treatments for chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic lymphoma.
GlaxoSmithKline plc announced today that a peer-reviewed study issued online by the New England Journal of Medicine has reported that GSK's FluLaval® Quadrivalent reduced flu cases among children ages 3-8 by 55.4% overall and lowered the risk of developing moderate-to-serious flu illness by 73.1%.
› Verified 8 days ago
Brian Knutson, PT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 2838 Oswell St, Bakersfield, CA 93306 Phone: 661-377-1700 | |
Julie Marie Contos, PTA Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 3850 Riverlakes Dr, Bakersfield, CA 93312 Phone: 661-529-5303 | |
Fernando Garcia-rodriguez, PTA Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1801 Oak St, Bakersfield, CA 93301 Phone: 661-327-9800 | |
Jay H. Yoo, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 5251 Office Park Dr., Blgd. 100 Ste. 120, Bakersfield, CA 93309 Phone: 661-336-0700 Fax: 661-336-0200 | |
Alan Inocentes, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 3733 San Dimas St, Bakersfield, CA 93301 Phone: 800-353-5400 | |
Tara Schulze, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1820 Chester Ave, Bakersfield, CA 93301 Phone: 661-631-8793 | |
Chris Sung-il Yoon, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 5001 Commerce Dr, Suite #100, Bakersfield, CA 93309 Phone: 661-325-8375 Fax: 661-633-3799 |